Explore pitfalls and blind spots and how to avoid them in executing a reliable strategy and a roadmap for successful expansion.

The U.S. market is both extremely attractive and overwhelming. To gain fast traction and reliable growth in the U.S., companies need exceptional strategy and execution. This is especially true in the health care and life sciences space given its complexities.

Hear directly from experts on why it may not be enough to file a U.S. patent, the importance of due diligence, what realistic regulatory time and budget estimates are, and get a candid view of U.S. investor expectations. Includes Audience Q&A.

Expert Panel

• Glen Gaddy - Managing Member of Robin Hood Ventures, leading Mid-Atlantic Angel Investor group
• Christopher Halliday - Partner, DLA Piper
• Norris Turner - President & CEO, Turner Healthcare Quality Consulting
• Jannik Grodt Schmidt - Head of Life Science USA, Innovation Norway
• Mike Ryan - Executive Vice President, Europe, EVERSANA
• Arne Madsen - President, Scan MedPartners
• Daniel Rosenbaum - Consulting CFO, Burkland Associates